Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-201 in Chinese adults with moderate-to-severe atopic dermatitis
CTR20231224Phase 2Completed
- Sponsor
- 苏州康乃德生物医药有限公司
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rademikibart in atopic dermatitis (AD), sponsored by 苏州康乃德生物医药有限公司. Started Jul 2023; status: completed.
02
Drugs
rademikibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20231224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231224.